Estradiol/dydrogesterone

{{Short description|Combination drug}}

{{Drugbox

| drug_name =

| image = Estradiol.svg

| width = 225px

| caption = Estradiol

| image2 = Dydrogesterone.svg

| width2 = 225px

| caption2 = Dydrogesterone

| type = combo

| component1 = Estradiol

| class1 = Estrogen

| component2 = Dydrogesterone

| class2 = Progestogen; Progestin

| tradename = Femoston, Climaston, Femaston

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU = S4

| legal_CA =

| legal_UK = POM

| legal_UK_comment = {{cite web | title=Femoston 1/10 mg Film-coated Tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=23 November 2016 | url=https://www.medicines.org.uk/emc/product/5523/smpc | access-date=23 August 2020}}

| legal_US = Rx-only

| routes_of_administration = By mouth

| class = Estrogen; Progestin; Progestogen

| CAS_number = 189038-72-0

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = E2/DYD

}}

Estradiol/dydrogesterone (E2/DYD), sold under the brand name Femoston among others, is a combination of estradiol (E2), an estrogen, and dydrogesterone (DYD), a progestin, which is used in menopausal hormone therapy, specifically to treat and prevent hot flashes and osteoporosis, in postmenopausal women.{{cite web | title = Femoston-conti 1mg/ 5mg film-coated tablets Package Leaflet | url = https://www.medicines.org.uk/emc/files/pil.1347.pdf | work = Mylan Products Ltd. | date = September 2023 | via = Electronic Medicines Compendium (EMC) }}{{cite journal | vauthors = Foster RH, Balfour JA | title = Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women | journal = Drugs & Aging | volume = 11 | issue = 4 | pages = 309–332 | date = October 1997 | pmid = 9342560 | doi = 10.2165/00002512-199711040-00006 | s2cid = 1733575 }}{{cite journal | vauthors = Stevenson JC, Panay N, Pexman-Fieth C | title = Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety | journal = Maturitas | volume = 76 | issue = 1 | pages = 10–21 | date = September 2013 | pmid = 23835005 | doi = 10.1016/j.maturitas.2013.05.018 }} It is taken by mouth and contains 0.5, 1, or 2 mg E2 and 2.5, 5, 10, or 20 mg DYD per tablet.{{cite book| vauthors = Cartwright S, Godlee C | chapter = Gynocology |title=Churchill's Pocketbook of General Practice E-Book| chapter-url = https://books.google.com/books?id=uHGFhWN9xBkC&pg=PA55|date=20 January 2012|publisher=Elsevier Health Sciences|isbn=978-0-7020-5073-2|pages=55–}}{{cite book| vauthors = Teotia N |title=Living With the Menopause|url=https://books.google.com/books?id=dTjoCwAAQBAJ&pg=PT37|date=8 April 2016|publisher=Fusion Books|isbn=978-93-85975-08-0|pages=37–}}{{cite book | vauthors = Mazza D | chapter = Menopause and Osteoporosis |title=Women's Health in General Practice| chapter-url = https://books.google.com/books?id=_Q7IO4ACO1cC&pg=PA269|date=7 January 2011|publisher=Elsevier Health Sciences|isbn=978-0-7295-7871-4|pages=269–}} The medication is marketed widely throughout the world.{{Cite web |url= https://www.drugs.com/international/dydrogesterone.html |title = Dydrogesterone | work = Drugs.com }} It is not available in the United States or Canada.